Compare KRNY & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | CABA |
|---|---|---|
| Founded | 1884 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.5M | 495.7M |
| IPO Year | 2014 | 2019 |
| Metric | KRNY | CABA |
|---|---|---|
| Price | $9.77 | $3.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.25 | ★ $14.50 |
| AVG Volume (30 Days) | 685.4K | ★ 4.2M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 35.71 | 10.26 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $17.32 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $6.23 | $1.44 |
| 52 Week High | $10.08 | $4.23 |
| Indicator | KRNY | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 58.51 |
| Support Level | $9.36 | $3.12 |
| Resistance Level | $9.97 | $3.34 |
| Average True Range (ATR) | 0.22 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 46.55 | 68.32 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.